Allarity Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line with GAAP EPS of -$0.21 vs. -$0.25 expected, and a net loss of $3.41M vs. $4.04M expected. While the net loss was narrower than anticipated, the company generated zero revenue, in line with expectations for this clinical-stage biotech. Operating expenses fell YoY to $2.67M, but liquidity remains a primary concern as the company relies on a new $20M promissory note structure from Streeterville Capital to fund the next 12 months of operations.